2m 2m 2m 2m 2m 2m 2m
CRINETICS PHARMA (CRNX)
NASDAQ
$36.07+$0.68 (+1.94%)
Price as of Jun 23, 2026 6:47 PM EDT- $3.7BMarket Cap
- 18.29%1-Year Change
- BiotechnologyIndustry
CRINETICS PHARMA (CRNX)
$36.07+$0.68 (+1.94%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 5.4M +421.66% | 1.0M -74.11% | 4.0M -15.28% | 4.7M +339.42% | |
Cost of Revenue | 1.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 4.3M +318.09% | 1.0M -74.11% | 4.0M -15.28% | 4.7M +339.42% | |
Sales and Marketing Expense | 191.3M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -332.1M +38.27% | -240.2M +42.50% | -168.5M +29.41% | -130.2M +54.56% | |
Depreciation and Amortization Expense | 3.9M +39.68% | 2.8M +153.64% | 1.1M +11.70% | 983,000 +6.62% | |
Total Operating Expenses | 524.5M +54.30% | 339.9M +49.98% | 226.6M +31.28% | 172.6M +58.69% | |
Operating Profit | -516.8M +52.50% | -338.9M +52.22% | -222.6M +32.60% | -167.9M +55.88% | |
Interest Income | 52.0M +25.47% | 41.4M +208.39% | 13.4M +211.23% | 4.3M +2,649.68% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 52.0M +25.47% | 41.4M +208.39% | 13.4M +211.23% | 4.3M +2,649.68% | |
Total Nonoperating Income and Expense | 51.6M +26.19% | 40.9M +208.17% | 13.3M +166.93% | 5.0M +8,054.10% | |
Income before Taxes | -465.1M +37.27% | -338.9M +52.22% | -222.6M +32.60% | -167.9M +55.88% | |
Income Taxes | 180,000 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -465.3M +55.93% | -298.4M +39.10% | -214.5M +30.88% | -163.9M +52.28% | |
Net Income from Continuing Operations Applicable to Common | -465.3M +55.93% | -298.4M +39.10% | -214.5M +30.88% | -163.9M +52.28% | |
Basic EPS and Net Income | -4.95 +34.15% | -3.69 0.00% | -3.69 +17.14% | -3.15 +12.50% | |
Diluted EPS and Net Income | -4.95 +34.15% | -3.69 0.00% | -3.69 +17.14% | -3.15 +12.50% | |
Basic Weighted Average Shares | 94.1M +16.43% | 80.8M +39.11% | 58.1M +11.71% | 52.0M +35.24% | |
Diluted Weighted Average Shares | 94.1M +16.43% | 80.8M +39.11% | 58.1M +11.71% | 52.0M +35.24% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 101.5M -61.62% | 264.5M +381.89% | 54.9M +68.02% | 32.7M -83.72% | |
Short-Term Investments | 926.4M -14.98% | 1.1B +116.32% | 503.7M +66.91% | 301.8M +126.86% | |
Cash and Cash Equivalents and Short-Term Investments | 1.0B -24.09% | 1.4B +142.42% | 558.6M +67.02% | 334.4M +0.22% | |
Total Current Assets | 1.0B -23.78% | 1.4B +139.55% | 574.2M +66.33% | 345.2M +0.13% | |
Accumulated Depreciation | 8.0M +2.85% | 7.7M +52.57% | 5.1M +24.09% | 4.1M +17.36% | |
Property and Plant and Equipment and Net | 14.3M +18.46% | 12.1M +10.91% | 10.9M +210.89% | 3.5M +23.89% | |
Total Long-Term Assets | 14.3M +405.34% | 2.8M +41.45% | 2.0M +5,305.41% | 37,000 -98.69% | |
Total Assets | 1.1B -21.49% | 1.4B +125.79% | 635.4M +80.41% | 352.2M +0.33% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 85.1M +42.54% | 59.7M +35.82% | 43.9M +58.50% | 27.7M +73.32% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | 30.0M 0.00% | |
Total Long-Term Liabilities | 3.2M +290.83% | 829,000 -98.42% | 52.3M +543.75% | 8.1M +164.14% | |
Total Liabilities | 134.2M +22.21% | 109.8M +14.07% | 96.2M +168.49% | 35.8M +87.97% | |
Retained Earnings | -1.4B +48.87% | -952.1M +45.65% | -653.7M +48.85% | -439.2M +59.55% | |
Total Stockholders Equity | 992.1M -25.11% | 1.3B +145.74% | 539.1M +70.43% | 316.3M -4.70% | |
Total Shares Outstanding | 95.6M +2.85% | 92.9M +36.31% | 68.2M +26.54% | 53.9M +13.19% | |
Cash Flow | |||||
Cash from Operating Activities | -377.9M +67.24% | -226.0M +35.88% | -166.3M +44.36% | -115.2M +30.05% | |
Capital Expenditures | 5.8M +49.90% | 3.8M -18.00% | 4.7M +183.09% | 1.7M +279.82% | |
Cash from Investing Activities | 173.9M +130.25% | -574.8M +186.82% | -200.4M +15.19% | -174.0M +208.02% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 40.6M -95.98% | 1.0B +159.79% | 388.9M +218.90% | 122.0M -51.73% | |
Financials Ratio | |||||
Gross Margin | 80.15% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -9,534.48% -70.77% | -32,613.47% +487.93% | -5,547.17% +56.52% | -3,544.06% -64.53% | |
Return on Assets | -36.34% +26.04% | -28.83% -33.64% | -43.45% -6.81% | -46.62% +15.74% | |
Return on Equity | -40.17% +25.45% | -32.02% -36.16% | -50.16% -0.82% | -50.57% +17.65% | |
Revenue Growth | 421.66% +668.97% | -74.11% +384.88% | -15.28% -104.50% | 339.42% -76.07% | |
Current Ratio | 12.32 -46.53% | 23.04 +76.37% | 13.07 +4.94% | 12.45 -42.23% | |
Cash Ratio | 1.19 -73.07% | 4.43 +254.79% | 1.25 +6.01% | 1.18 -90.61% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow